Literature DB >> 19224589

The duration of the motor response to apomorphine boluses is conditioned by the length of a prior infusion in Parkinson's disease.

Julia Vaamonde1, José M Flores, Roberto Weisser, Ramón Ibañez, José A Obeso.   

Abstract

"Pulsatile" administration of levodopa has been invocated a relevant factor for motor fluctuations in Parkinson's disease (PD). We studied dopaminergic sensitivity to apomorphine in 10 parkinsonian patients with motor fluctuations. Patients were tested as follows: the minimal effective dose of apomorphine (MED-1) was administered in the morning to induce an on response. Fifteen minutes after this motor response had disappeared, an apomorphine infusion was initiated and maintained to ensure on periods of three different durations on different days. Infusion lasted for approximately 30, 60 and 90 minutes. Subsequently, the infusion was stopped, and after 15 minutes in the off state, a second bolus of apomorphine (MED-2) was given. The mean infusion doses were 49.2 +/- 5.4, 108.4 +/- 10.3, and 150 +/- 8.2 mg. These elicited on periods of 48.2 +/- 4.1, 110 +/- 4.5, and 195 +/- 3.8 minutes. The MED-2 elicited on responses with a duration of 30 +/- 4.5, 18.4 +/- 3.2, and 11.2 +/- 4.1 minutes. The duration of the on response induced by the apomorphine infusions correlated inversely (P < 0.01) with the on induced by the MED-2 of apomorphine. Our findings indicate that a continuous dopaminergic stimulus may induce pharmacodynamic changes associated with tolerance in PD patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19224589     DOI: 10.1002/mds.22234

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  3 in total

Review 1.  Targeting the neurovascular unit for treatment of neurological disorders.

Authors:  Reyna L Vangilder; Charles L Rosen; Taura L Barr; Jason D Huber
Journal:  Pharmacol Ther       Date:  2010-12-21       Impact factor: 12.310

2.  Part 2: Introduction to the Pharmacotherapy of Parkinson's Disease, With a Focus on the Use of Dopaminergic Agents.

Authors:  George DeMaagd; Ashok Philip
Journal:  P T       Date:  2015-09

Review 3.  Pharmacological Insights into the Use of Apomorphine in Parkinson's Disease: Clinical Relevance.

Authors:  Manon Auffret; Sophie Drapier; Marc Vérin
Journal:  Clin Drug Investig       Date:  2018-04       Impact factor: 2.859

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.